Publication | Open Access
Calpain‐mediated down‐regulation of myelin‐associated glycoprotein in lysophosphatidic acid‐induced neuropathic pain
40
Citations
21
References
2010
Year
Pain MedicineSynaptic TransmissionNeuropathic PainMolecular PainCalpain ActivationPeripheral NerveMyelin ProteinsNeurologyNeuropathologyHealth SciencesMolecular PhysiologyMyelin‐associated GlycoproteinNeuropharmacologySciatic Nerve InjuryPharmacologyPain ResearchNeurophysiologyPhysiologyNeurosciencePain MechanismMolecular NeurobiologyMedicine
Lysophosphatidic acid receptor (LPA(1)) signaling initiates neuropathic pain through demyelination of the dorsal root (DR). Although LPA is found to cause down-regulation of myelin proteins underlying demyelination, the detailed mechanism remains to be determined. In the present study, we found that a single intrathecal injection of LPA evoked a dose- and time-dependent down-regulation of myelin-associated glycoprotein (MAG) in the DR through LPA(1) receptor. A similar event was also observed in ex vivo DR cultures. Interestingly, LPA-induced down-regulation of MAG was significantly inhibited by calpain inhibitors (calpain inhibitor X, E-64 and E-64d) and LPA markedly induced calpain activation in the DR. The pre-treatment with calpain inhibitors attenuated LPA-induced neuropathic pain behaviors such as hyperalgesia and allodynia. Moreover, we found that sciatic nerve injury activates calpain activity in the DR in a LPA(1) receptor-dependent manner. The E-64d treatments significantly blocked nerve injury-induced MAG down-regulation and neuropathic pain. However, there was no significant calpain activation in the DR by complete Freund's adjuvant treatment, and E-64d failed to show anti-hyperalgesic effects in this inflammation model. The present study provides strong evidence that LPA-induced calpain activation plays a crucial role in the manifestation of neuropathic pain through MAG down-regulation in the DR.
| Year | Citations | |
|---|---|---|
Page 1
Page 1